Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA508 versus NovoRapid dual insulin degludec/aspart in type 2 diabetes
ChiCTR2400088672Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Change in HbA1c from baseline at week 24. Started Aug 2024; status: recruiting.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400088672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088672.